Loading...
Docoh

Pieris Pharmaceuticals (PIRS)

Utility
Novel Proteins Specific for CD137
12 May 22
The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases.
Marlon HINNER, Christine ROTHE, Shane OLWILL, Andrea ALLERSDORFER, Rachida Siham BEL AIBA
Filed: 19 Jan 22
Utility
Lipocalin Muteins with Binding Affinity for LAG-3
31 Mar 22
The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases.
Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
Filed: 12 Oct 21
Utility
Proteins specific for CD137
1 Mar 22
The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases.
Marlon Hinner, Christine Rothe, Shane Olwill, Andrea Allersdorfer, Rachida Siham Bel Aiba
Filed: 4 May 16
Utility
Anti-cancer Fusion Polypeptide
30 Dec 21
The disclosure provides a fusion polypeptide specific for both CD137 and GPC3, which fusion polypeptide can be useful for directing CD137 clustering and activation to GPC3-positive tumor cells.
Marlon Hinner, Rachida Siham Bel Aiba, Christine Rothe, Shane Olwill, Corinna Schlosser
Filed: 5 Feb 21
Utility
Novel Fusion Protein Specific for CD137 and PD-L1
25 Nov 21
The disclosure provides fusion proteins specific for both CD 137 and PD-L1, which fusion protein can be used to co-stimulate lymphocyte activation in a PD-L1-target-dependent manner.
Marina Pavlidou, Christine Rothe, Shane Olwill, Rachida Bel Aiba, Marlon Hinner, Janet Peper, Lucia Pattarini, Alix Scholer-Dahirel
Filed: 31 Jul 19
Utility
Lipocalin muteins with binding affinity for LAG-3
9 Nov 21
The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases.
Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
Filed: 18 Jan 18
Utility
Combination Therapies Comprising CD137/HER2 Bispecific Agents and PD-1 Axis Inhibitors and Uses Thereof
12 Aug 21
The disclosure provides compositions and methods for treating previously treated specific HER2-positive advanced or metastatic solid tumors.
Ingmar Bruns, Louis Matis, Shane Olwill, Thomas Jaquin
Filed: 27 Aug 19
Utility
Anti-cancer Fusion Polypeptide
1 Jul 21
The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu-positive tumor cells.
Marlon Hinner, Christine Rothe, Shane Olwill, Rachida Siham Bel Aiba, Ulrich Moebius, Corinna Schlosser, Thomas Jean Jaquin
Filed: 12 Nov 20
Utility
Proteins specific for calcitonin gene-related peptide
15 Jun 21
The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine.
Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
Filed: 8 Jul 19
Utility
Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)
15 Jun 21
The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis.
Rachida Siham Bel Aiba, Andrea Allersdorfer, Alexander Wiedenmann, Christine Rothe, Shane Olwill, Hendrik Gille, Laurent Audoly
Filed: 13 Nov 19
Utility
Methods for Preventing or Treating Certain Disorders by Inhibiting Binding of IL-4 And/or IL-13 to Their Respective Receptors
20 May 21
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof.
Andreas HOHLBAUM, Laurent Audoly, Beverly Koller
Filed: 5 Nov 20
Utility
Fusion molecules
16 Mar 21
The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection.
Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
Filed: 24 Apr 19
Utility
Multi-specific polypeptide useful for localized tumor immunomodulation
23 Feb 21
The disclosure provides a multi-specific polypeptide with a first moiety specific for a tumor-associated antigen on tumor cell surface and a second moiety specific for an immune checkpoint protein, which multi-specific polypeptide can be useful for biasing a T-cell-mediated response to a tumor micro-environment.
Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer, Rachida Bel Aiba, Gabriele Matschiner, Bradley Lunde
Filed: 12 Jan 15
Utility
Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response
23 Feb 21
The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases.
Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Rachida Siham Bel Aiba, Shane Olwill, Timo Eichner
Filed: 30 Oct 19
Utility
Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptides
9 Feb 21
The disclosure provides a fusion polypeptide specific for both CD137 and GPC3, which fusion polypeptide can be useful for directing CD137 clustering and activation to GPC3-positive tumor cells.
Marlon Hinner, Rachida Siham Bel Aiba, Christine Rothe, Shane Olwill, Corinna Schlosser
Filed: 18 May 16
Utility
Tear lipocalin muteins binding IL-4 r alpha
26 Jan 21
The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha.
Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
Filed: 24 Jan 19
Utility
Anti-cancer fusion polypeptide
14 Dec 20
The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu-positive tumor cells.
Marlon Hinner, Christine Rothe, Shane Olwill, Rachida Siham Bel Aiba, Ulrich Moebius, Corinna Schlosser, Thomas Jean Jaquin
Filed: 3 May 16
Utility
Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
7 Dec 20
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot # P05112 and/or the ligand of Uniprot # P35225 from binding to their respective receptors to a subject in need thereof.
Andreas Hohlbaum, Laurent Audoly, Beverly Koller
Filed: 15 Jul 19
Utility
Novel Specific-binding Polypeptides and Uses Thereof
2 Dec 20
The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7.
Marlon Hinner, Alexander Wiedenmann, Andrea Allersdorfer
Filed: 5 Aug 20
Utility
Muteins of Human Lipocalin 2 (LCN2,HNGAL) with Affinity for a Given Target
30 Sep 20
The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity.
Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
Filed: 5 Mar 20
Patents are sorted by USPTO publication date, most recent first